President and CEO
Rob Kill assumed the role of President and CEO of Cogentix Medical when Uroplasty merged with Vision-Sciences in March 2015. He was named President and CEO of Uroplasty, Inc. in July 2013 and has served on the Board of Directors since 2010. He also serves as an Operating Partner of Altamont Capital Partners, a private equity firm with over $1 billion in capital. Prior to Uroplasty, Mr. Kill served as Chairman & CEO of Virtual Radiologic Corporation, a telemedicine provider of technology-enabled outsourced radiology solutions to over 2,500 hospitals. Before joining Virtual Radiologic, he was President of Misys Physician Systems, a developer of electronic medical record and practice management software applications serving more than 85,000 physician customers across the United States. Earlier in his career, Mr. Kill spent 10 years with Baxter Healthcare, where he held senior leadership roles in operations, marketing and sales. He received a B.A. in Economics from the University of Notre Dame. Mr. Kill brings to our board substantial experience and insight in executive management of rapidly growing public companies, particularly companies focused on healthcare.
Chief Financial Officer
Brett Reynolds assumed the role of Chief Financial Officer for Cogentix Medical when Uroplasty merged with Vision-Sciences in March 2015. He joined Uroplasty as Senior Vice President and Chief Financial Officer in August 2013. From 2005 until its acquisition by Baxter International Inc. in February 2012, Mr. Reynolds was the Chief Financial Officer and Vice President of Finance of Synovis Life Technologies, Inc., a publicly-held medical device manufacturer headquartered in the St. Paul, MN. From 2012 until becoming an officer of Uroplasty, Mr. Reynolds was the site leader of Baxter in the Twin Cities responsible for the remainder of the Synovis operations. Prior to Synovis, Mr. Reynolds served in executive financial positions at Chiquita Processed Foods, Arthur Andersen and Deloitte & Touche. Mr. Reynolds is a Certified Public Accountant and holds a BS in Accounting and an MBA from the University of Minnesota’s Carlson School of Management.
Senior Vice President of Global Sales and Marketing
Darin Hammers assumed the role of Senior Vice President of Sales and Marketing of Cogentix Medical when Uroplasty merged with Vision-Sciences in March 2015. He joined Uroplasty as Vice President of Global Sales in January 2013. He was previously a Vice President of Sales for Bard Medical Divisions, of CR Bard based in Covington, GA, focused on Urology care products. Prior to that, Mr. Hammers spent more than 12 years with Boston Scientific in various sales leadership positions in the Urology/Gynecology areas. Mr. Hammers holds a BS in Marketing from the University of Southern Indiana and received his MBA from Emory University.
Vice President of Healthcare Affairs
Dan Merz assumed the role of Vice President of Healthcare Affairs for Cogentix Medical when Uroplasty merged with Vision-Sciences in March 2015. He joined Uroplasty as the Vice President of Healthcare Affairs in April 2014. In this role, he oversees the company's efforts to gain global coverage for PTNS and Macroplastique therapies through the strategic development and demonstration of the efficiency, effectiveness and overall value of the Company’s products to payers and providers. He joins Uroplasty with fifteen years of medical device experience at various levels of management, specifically in driving commercial success through enhanced reimbursement, novel clinical research and efficient regulatory clearances. Mr. Merz holds a Bachelor of Science degree from Northwestern University in Biomedical Engineering and has a deep background in strategic planning, organizational development, process reengineering and successful influence on medical organizations and reimbursement policy. Most recently, he directed the clinical affairs program at St. Jude Medical in Plymouth, Minnesota, where he was accountable for the global trans-catheter and surgical heart valve clinical programs. Prior to that, he oversaw the clinical and regulatory team supporting the global BPH capital equipment business in Minnesota and California for American Medical Systems, a leading medical device manufacturer specializing in urology and pelvic health.
Dr. Suranjan Roychowdhury
Vice President of Research & Development and Clinical Affairs
Dr. Suranjan Roychowdhury assumed the role of Vice President of Research & Development and Clinical Affairs for Cogentix Medical when Uroplasty merged with Vision-Sciences in March 2015. He joined Uroplasty as Vice President of Research & Development and Clinical Affairs in January 2014. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the Company's product pipeline and clinical trials. Dr. Roychowdhury has more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices. Dr. Roychowdhury served for more than eight years in advancing executive roles with American Medical Systems, including leadership of R&D as well as the Clinical, Regulatory, and Healthcare Economics functions for the $230 million Men's Health division. Prior to joining Uroplasty, Dr. Roychowdhury was with Vascular Solutions, a Minnesota-based cardiovascular medical device company. He has also served in leadership roles with Sulzer Spine-Tech (now Zimmer Spine), Boston Scientific, and Schneider USA (Pfizer). Dr. Roychowdhury holds a B.Tech in Metallurgical Engineering from the Indian Institute of Technology at Varanasi, and M.S. and Ph.D. degrees in Materials Science & Engineering from the University of Delaware. He is the author of several publications on urology and cardiovascular topics. In addition, he holds 20 issued US patents for medical devices in Cardiology, Orthopedics, Urology and Drug Delivery.